Pugliese Nicola, De Deo Diletta, Soleri Matteo, Colapietro Francesca, Vettor Roberto, Aghemo Alessio
Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, MI, Italy.
Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Via A. Manzoni 56, 20089 Rozzano, MI, Italy.
Nutrients. 2025 May 12;17(10):1644. doi: 10.3390/nu17101644.
The prevalence and socioeconomic impact of Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing. Despite the recent Food and Drug Administration (FDA) approval of Resmetirom as the first drug for patients with Metabolic dysfunction-associated steatohepatitis (MASH) and significant fibrosis, and several ongoing clinical trials, lifestyle changes aimed at achieving sustained weight loss remain a cornerstone in the management of these patients. In addition to regular and structured physical activity, diet is crucial. Several studies have demonstrated the benefits of the Mediterranean diet in this regard, and there is also emerging evidence on the vegetarian diet and its different patterns. This review aims to summarize the currently available evidence on the potential benefits of a vegetarian diet in patients with MASLD, as well as exploring its potential limitations.
代谢功能障碍相关脂肪性肝病（MASLD）的患病率及其社会经济影响正在上升。尽管美国食品药品监督管理局（FDA）最近批准了Resmetirom作为治疗代谢功能障碍相关脂肪性肝炎（MASH）和显著肝纤维化患者的首款药物，并且还有几项正在进行的临床试验，但旨在实现持续体重减轻的生活方式改变仍然是这些患者管理的基石。除了规律且有组织的体育活动外，饮食也至关重要。多项研究已证明地中海饮食在这方面的益处，关于素食饮食及其不同模式也有新出现的证据。本综述旨在总结目前关于素食饮食对MASLD患者潜在益处的现有证据，并探讨其潜在局限性。
